Kymera Therapeutics receives U.S. FDA FTD for KT-333

Kymera Therapeutics anounced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation , FTD, to KT-333 for the treatment of R/R Cutaneous T-cell Lymphoma, CTCL, and R/R Peripheral T-cell Lymphoma, PTCL. “The KT-333 Fast Track designation highlights the promise of degrading STAT3, a protein that has historically been undruggable, for the treatment of patients with CTCL and PTCL,” said Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics. “We look forward to providing an update on the KT-333 Phase 1 clinical trial later this year, including initial evaluation of its antitumor activity in the target patient populations, and to working with the lymphoma community to rapidly advance this first-in-class heterobifunctional degrader in CTCL and PTCL in addition to exploring its potential in other cancers.”